CHRISTOPHER NICHOLS, PH.D.
Christopher has experience with strategic counseling for patent, trademark, and copyright matters including preparation, prosecution, licensing, due diligence, and enforcement. Christopher’s practice focuses on representation of biotechnology, pharmaceutical, and chemical companies of all sizes, including the preparation and prosecution of US and foreign patent applications; patentability, infringement, and validity due diligence analyses and opinions. He has legal and technical experience with novel proteins and recombinant DNA; iRNA technology; antibody technology; transgenic animals; gene therapy; bioinformatics; genomics; antimicrobial and cancer therapeutics; imaging and diagnostics, including immunoassays and arrays; plant cell and microbial fermentation methods and equipment; plants; vaccines; and therapeutic biologics. In addition, Christopher has research experience in neuroscience and physiology. Prior to joining the Firm, Dr. Nichols served as General Counsel for a Start-Up, overseeing all of the legal matters for the company, including intellectual property, state and federal regulatory matters, and capital fundraising.
Christopher also worked as a NIH Postdoctoral Research Fellow and served as a biotechnology patent examiner in the United States Patent & Trademark Office.
- Randolph Williams Award for outstanding Pro Bono Service, 2010
“How are Diagnostic Methods Handled by the USPTO” Parts I and II Nichols, Peña, and Posorske Intellectual Property & Technology Law Journal (February and March 2018)
“Marking Your Territory in the Patent World: The Basics of Physical vs. Virtual Patent Marking.” Vivarelli, Nichols, and Hosseini Client Alert from the Chemical and Biotech Patent Practice at Hunton & Williams (2018)
“Novartis and Gilead Eviscerate Patent Term Adjustment” Posorske and Nichols Intellectual Property & Technology Law Journal (2016) 28(2)11–15
“Will Patentees Received Patent Term Adjustment After Novartis and Gilead?” Posorske and Nichols Client Alert from the Chemical and Biotech Patent Practice at Hunton & Williams (2015)
“USPTO Begins to Apply Myriad to Pending Patent Applications.” Posorske and Nichols Client Alert from the Chemical and Biotech Patent Practice at Hunton & Williams (2014)
“2012 Eastern District of Virginia Intellectual Property Year in Review.” From Hunton & Williams (2013) Brent Van Normal (editor) and Nichols [contributor]
“New Opportunities for Seeking Patent Term Adjustment Under the AIA.” Posorske and Nichols Client Alert from the Chemical and Biotech Patent Practice at Hunton & Williams (2013)
“Preserving Your Right to Patent Term Adjustment: The Exelixis Decision and Lessons from Wyeth.” Posorske, Nichols, and Vockrodt Client Alert from the Chemical and Biotech Patent Practice at Hunton & Williams (2012)
“‘Micro Entity’ Status Benefits are Limited.” Posorske, Suchyta, and Nichols Client Alert from the Chemical and Biotech Patent Practice at Hunton & Williams (2012)
“Merck. v. Integra: Supreme Court Broadly Interprets Safe Harbor Exemption.” Aksman, Messplay, Heisey, and Nichols Client Alert from the Chemical and Biotech Patent Practice at Hunton & Williams (2005)
“Hsp70 dynamics in vivo: effect of heat shock and protein aggregation.” Zeng, Bhasin, Wu, Lee, Maffi, Nichols, Lee, Taylor, Greene, and Eisenberg Journal of Cell Science (2004) 117: 4991–5000
“Two Invariant Tryptophans on the α1 Subunit Define Domains Necessary for GABAA Receptor Assembly” Srinivasan, Nichols, Lawless, Olsen, and Tobin Journal of Biological Chemistry (1999) 274 (38): 26633–26638
- George Washington University Law School, JD, 2009
- UCLA, PhD, Physiology, 2001
- UCSB, BA, Biology 1995
- District of Columbia
- US Patent and Trademark Office
- District Court for the Central District of California
- District Court for the Southern District of California
- District Court for the Eastern District of California